Clinical use and toxicities of bortezomib in pediatric patients: a systematic review

Clinical use and toxicities of bortezomib in pediatric patients: a systematic review

BackgroundProteasome inhibitors (PIs) are FDA-approved to treat adult malignancies. The PI, Bortezomib (BTZ), has been used off-label in pediatric patients but its safety profile in these patients has yet to be systematically assessed. We sought to review the pediatric safety profile of BTZ based on...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zachary C. LeBlanc, Averill Clapp, Samantha Kaplan, Carrie J. Shawber, June K. Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Pharmacology
Subjects:	bortezomib adverse events pediatric safety systematic review proteasome inhibitors
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1661493/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Senescence Program is Reduced in Proteasome Inhibitor Bortezomib-Resistant PC3 Prostate Cancer Cell Line
by: Ertan Kanbur, et al.
Published: (2023-06-01)

Immune checkpoint inhibitors and the pediatric rheumatologist: a pediatric needs assessment
by: John Storwick, et al.
Published: (2025-07-01)

138. PI3K Activation Drives Protein Homeostasis Pathology in Venous Malformations
by: Zachary C. LeBlanc, AB, et al.
Published: (2025-05-01)

Pharmacovigilance and signal detection of adverse drug events associated with proteasome inhibitors in multiple myeloma: a real-world analysis using the FAERS database
by: JunYun Luo, et al.
Published: (2025-12-01)

FLAG with Bortezomib in Children and Adolescents with Relapsed/Refractory Acute Myeloid Leukemia in a Resource-Limited Setting: A Single-Center Experience from India
by: Dipesh Dave, et al.

Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)

Macrocusteio do uso do Bortezomibe no tratamento do Mieloma Múltiplo na perspectiva do SUS
by: Mariana Andrades Fiorini Monteiro Novo, et al.
Published: (2025-07-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Effects of bortezomib on intracellular antioxidant and apoptosis in HepG2cells
by: Grażyna Świderska-Kołacz, et al.
Published: (2025-04-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide
by: Uday Kulkarni, et al.
Published: (2020-04-01)

Treatment-free survival to bortezomib combined with dexamethasone in patients with refractory/relapsed pure red cell aplasia: a prospective clinical study
by: Lele Zhang, et al.
Published: (2025-12-01)

Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum/Golgi stress and apoptosis
by: Chang-Tze Ricky Yu, et al.
Published: (2024-12-01)

Effect of the combination of remifentanil and neuromuscular blockers in pediatric endotracheal intubation: a prospective, double-blinded, randomized clinical trial
by: Lanxin Qiao, et al.
Published: (2025-08-01)

The efficacy of bortezomib during induction therapy in patients with high-risk acute lymphoblastic leukemia
by: Camila Terreros-Palacios, et al.
Published: (2025-07-01)

Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management
by: Yi Gao, et al.
Published: (2025-03-01)

Incidence of postoperative respiratory adverse events and its predictors among pediatric surgical patients at Hawassa University Comprehensive Specialized Hospital: a prospective follow-up study
by: Tesfaye Asefa Hordofa, et al.
Published: (2025-05-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

Incidence and prevalence of organ toxicities in patients suffering from clear cell renal carcinoma treated with sunitinib and its impact on survival: a reference cancer center experience
by: Agata Sałek-Zań, et al.
Published: (2025-08-01)

Safety of oral JAK inhibitors in treating alopecia areata: a systematic review and network meta-analysis
by: Ziyu Qi, et al.
Published: (2025-08-01)

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)
by: M. Yu. Fedyanin, et al.
Published: (2023-06-01)

Evaluation of dermatologic adverse events associated with aromatase inhibitors: insights from the FAERS database
by: Yuan-Yuan Wu, et al.
Published: (2025-05-01)

Incidence and outcome characteristics of adverse event in surgery: an assessment based on systematic reviews of barbed suture
by: Xianlin Gu, et al.
Published: (2025-07-01)

Safety profile and dose-dependent adverse events of upadacitinib in randomized clinical trials: a systematic review and meta-analysis
by: Cong Zhang, et al.
Published: (2025-06-01)

Viral infections and related fatal adverse events associated with complement inhibitors for PNH: a real-world pharmacovigilance analysis in FAERS
by: Jinman Zhong, et al.
Published: (2025-08-01)

MIR4726EccDNA drives bortezomib resistance in multiple myeloma by enhancing MIR4726-5p/NXF1/NKIRAS2 axis dependent autophagy
by: Fangfang Li, et al.
Published: (2025-07-01)

Barriers and facilitators to pediatric tuberculosis management in India: a systematic review
by: Matthew Willis, et al.
Published: (2025-04-01)

Bortezomib-induced peripheral neuropathy in patients with multiple myeloma: pain syndrome and psychopathological aspects
by: E. Z. Irugova, et al.
Published: (2025-03-01)

Proteasome activity and subunit composition in endometrial hyperplasia and cancer
by: L. V. Spirina, et al.
Published: (2014-08-01)

Systematic review of MRI safety literature in relation to radiofrequency thermal injury prevention
by: Cassandra Baker, et al.
Published: (2024-09-01)

Adverse events of pharmacological interventions for insomnia disorder in adults: a systematic review and network meta-analysis
by: Changhong Lu, et al.
Published: (2025-07-01)

Clinical characteristic analysis of immune checkpoint inhibitor-related pituitary adverse events
by: Yufan ZHENG, et al.
Published: (2025-08-01)

Low triglyceride levels are associated with increased risk of immune-related adverse events in patients receiving immune checkpoint inhibitors
by: Nora Möhn, et al.
Published: (2025-12-01)

Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab
by: Hifaa Al Remawi, et al.
Published: (2025-12-01)

Possibilities of nimesulid administration in pediatric rheumatology
by: I. V. Babikova, et al.
Published: (2008-10-01)

Quality Assessment Tool within Systematic Reviews in Pediatric Dentistry in the Last Decade: Understanding the Threshold
by: Joe Mathew Cherian, et al.
Published: (2025-04-01)

Arthropathy associated with antitumor checkpoint inhibitors therapy: current understanding of the problem
by: A. D. Koltakova, et al.
Published: (2023-10-01)

Construction of predictive model for programmed death-1 inhibitor-related endocrine adverse events
by: Jiaying SHI, et al.
Published: (2025-08-01)

Analysis of the clinical characteristics of immune checkpoint inhibitor-related hypophysitis
by: Zhixiao WANG, et al.
Published: (2025-08-01)

Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience)
by: I. S. Romanov, et al.
Published: (2020-07-01)